Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 168Gliosarcoma 134Glioblastoma 130Brain Neoplasms 101Astrocytoma 86Central Nervous System Neoplasms 77Osteosarcoma 65Oligodendroglioma 61Neuroblastoma 58Sarcoma, Kaposi 56Glioma 51Neuroectodermal Tumors, Primitive, Peripheral 48Dendritic Cell Sarcoma, Interdigitating 44Burkitt Lymphoma 44Rhabdomyosarcoma 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 40Lymphoma 39Wilms Tumor 37Medulloblastoma 35Lymphoma, Non-Hodgkin 35Recurrence 32Sarcoma, Ewing 31Acquired Immunodeficiency Syndrome 30Lymphoma, Large B-Cell, Diffuse 29HIV Infections 29Ependymoma 28Leukemia 27Gastrointestinal Stromal Tumors 27Melanoma 26

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sinonasal undifferentiated carcinoma × Sarcoma × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡